Last reviewed · How we verify

NCT06912841: DBSMatchMaker

Deep Brain Stimulation (DBS) MatchMaker

ENROLLING BY INVITATION Last updated 13 April 2026
What this trial tests

trial in TOR1A in 500 participants. Enrolling by invitation.

Timeline
1 December 2024
Primary endpoint
1 December 2029
1 December 2030

Quick facts

Lead sponsorBoston Children's Hospital
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment500
Start date1 December 2024
Primary completion1 December 2029
Estimated completion1 December 2030
Sites1 location across United States

Conditions studied

Sponsor

Boston Children's Hospital

Who can join

Eligibility, any sex, with TOR1A or PANK2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

DBS Matchmaker (https://www.dbsmatchmaker.com) is a platform designed to connect clinicians worldwide who are treating rare movement disorders with deep brain stimulation (DBS). It facilitates global collaboration and knowledge sharing to enhance patient care by improving patient selection, counseling, treatment, and outcomes for individuals with movement disorders.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Decoding GNAO1 mutations using <i>Caenorhabditis elegans</i> model system: past approaches and future prospectives.
    Yadav S, Veliventi SS, Bhandari S, Gangurde S, et al · · 2025 · PMID 40771566 · DOI 10.3389/fncel.2025.1633744

Verify or expand the search:

Other Boston Children's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06912841.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing